secwatch / observer
8-K filed January 5, 2024, 6:59 PM ET ticker LAB CIK 0001162194
M&A confidence high sentiment positive materiality 0.85

STANDARD BIOTOOLS INC. (LAB): M&A transaction — Standard BioTools completes merger with SomaLogic; creates diversified life sciences tools leader

STANDARD BIOTOOLS INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carlos Paya

Director
LAB · STANDARD BIOTOOLS INC.
Effective
2024-01-05
Filed
January 5, 2024, 6:59 PM ET
Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors
Departed

Martin Madaus

Director
LAB · STANDARD BIOTOOLS INC.
Effective
2024-01-05
Filed
January 5, 2024, 6:59 PM ET
Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors
Departed

Laura Clague

Director
LAB · STANDARD BIOTOOLS INC.
Effective
2024-01-05
Filed
January 5, 2024, 6:59 PM ET
Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carlos Paya resigned as Director at STANDARD BIOTOOLS INC..

Action
resigned
Role
Director
Exact text from the filing
Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Madaus resigned as Director at STANDARD BIOTOOLS INC..

Action
resigned
Role
Director
Exact text from the filing
Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Clague resigned as Director at STANDARD BIOTOOLS INC..

Action
resigned
Role
Director
Exact text from the filing
Carlos Paya, M.D., Ph.D., Laura Clague and Martin Madaus, Ph.D. resigned from Standard BioTools’ board of directors
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

STANDARD BIOTOOLS INC.: Increased authorized common stock from 400,000,000 shares to 600,000,000 shares (effective 2024-01-04).

Change
charter amendment
Effective
2024-01-04
Exact text from the filing
On January 4, 2024, the Company filed a Certificate of Amendment to its Eighth Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the total number of shares of Standard BioTools Common Stock authorized for issuance thereunder from 400,000,000 shares to 600,000,000 shares (the “Charter Amendment”).
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

STANDARD BIOTOOLS INC. completed an acquisition involving SomaLogic, Inc. for 1.11 shares of Standard BioTools common stock per share (closed 2024-01-05).

Action
acquisition
Counterparty
SomaLogic, Inc.
Consideration
1.11 shares of Standard BioTools common stock per share
Closing
2024-01-05
Exact text from the filing
of the Merger, each issued and outstanding share of common stock of SomaLogic, par value $0.0001 per share (“SomaLogic Common Stock”), was converted into the right to receive 1.11 (the “Exchange Ratio”) shares of common stock of Standard BioTools, par value $0.001 per share (“Standard BioTools Common Stock”), and cash in lieu of fractional shares.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

STANDARD BIOTOOLS INC. shareholders approved To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the 'Standard BioTools Share Issuance Proposal'). at the 2024-01-04 meeting.

Proposal
merger approval
Outcome
passed
Meeting
2024-01-04
Exact text from the filing
Proposal 1. To approve the issuance of shares of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rule 5635(a) (the “Standard BioTools Share Issuance Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 125,739,416 5,186,617 127,586 None
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

STANDARD BIOTOOLS INC. shareholders approved To approve the Charter Amendment (the 'Standard BioTools Charter Amendment Proposal'). at the 2024-01-04 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-04
Exact text from the filing
Proposal 2. To approve the Charter Amendment (the “Standard BioTools Charter Amendment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 125,698,245 5,230,711 124,663 None
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

STANDARD BIOTOOLS INC. shareholders approved To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools’ named executive officers and to SomaLogic’s Chief Executive Officer that is based on or otherwise relates to the Merger. at the 2024-01-04 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2024-01-04
Exact text from the filing
Proposal 3. To approve, on a non-binding, advisory basis, the compensation that may become payable to Standard BioTools’ named executive officers and to SomaLogic’s Chief Executive Officer that is based on or otherwise relates to the Merger. Votes For Votes Against Abstentions Broker Non-Votes 119,441,699 11,267,991 343,929 None
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

STANDARD BIOTOOLS INC. shareholders approved To approve the A&R 2011 Plan Amendment. at the 2024-01-04 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2024-01-04
Exact text from the filing
Proposal 4. To approve the A&R 2011 Plan Amendment. Votes For Votes Against Abstentions Broker Non-Votes 119,362,194 11,536,749 154,676 None
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

STANDARD BIOTOOLS INC. shareholders approved To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment at the 2024-01-04 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-04
Exact text from the filing
Proposal 5. To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Standard BioTools Share Issuance Proposal and the Standard BioTools Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals. Votes For Votes Against Abstentions Broker Non-Votes 124,087,718 6,753,379 212,522 None
View on SEC.gov

Browse all governance changes →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR
accession 0001104659-24-001640
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.